Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism Syndromes

Plain-language summary

This study investigated the use of 18F-PMPBB3 (APN-1607) PET imaging as a marker for diagnosing tauopathy-related parkinsonism syndromes. It enrolled patients meeting diagnostic criteria for conditions such as Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and Alzheimer's disease, as well as neurologically healthy people (aged 20 to 90). This is a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

National Taiwan University Hospital

Intervention

18F-PMPBB3 (APN-1607) PET imaging

Start date

1/31/2022

Estimated completion

9/2/2024

Countries

Taiwan

Related genes

Locations

• Taipei, Taiwan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Written informed consent must be obtained before any assessment is performed.
2. Patients fulfill the criteria of United Kingdom Brain Bank Diagnostic Criteria of "possible" or "probably" PD.
3. Patients fulfill the criteria of MDS consensus criteria of "possible" or "probably" MSA.
4. Patients fulfill the criteria of NINDS-SPSP clinical criteria for the diagnosis of PSP "as possible" or "probably" PSP, and healthy volunteer with no clinically relevant finding on physical examination at screening visit.
5. Patients fulfill the criteria of Work Group on Frontotempotal Dementia and Pick's Disease of "possible" or "probably" FTD.
6. Patients fulfill the Armstrong's criteria of "possible" or "probably" CBGD.
7. Patients fulfill the National Institute on Aging-Alzheimer's Association (NIA-AA) workgroup for clinical diagnostic guidelines (NIA-AA-C) for MCI.
8. Patients fulfill the National Institute on Aging-Alzheimer's Association (NIA-AA) workgroup for clinical diagnostic guidelines (NIA-AA-C) for AD.
9. Neurologically normal controls.
10. Age range 20-90 years

Exclusion Criteria:

1. Implantation of metal devices including cardiac pacemaker, intravascular metal devices.
2. Major systemic diseases including coronary arterial disease, heart failure, uremia, hepatic failure, prominent strokes, acute myocardial infarction, poorly controlled diabetes, previous head injury, intracranial operation, hypoxia, sepsis or severe infectious diseases
3. Major psychiatric disorders, drug or alcohol abuse and major depression
4. Pregnant women or breast- feeding women